stemcellindex.com
Cell Therapeutics, Inc. (CTIC)Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkins lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington
Digg
| 
Reddit
| 
Mixx
| 
del.icio.us
| 
Stumble it! | 
| Share it
|
Comments submitted from other visitors |
More posts, Page # :
Cell Therapeutics, Inc Stem Cell Companies Stem Cell Stocks BioMimetic Therapeutics (BMTI) Pluristem Therapeutics-PTSI Osiris Therapeutics-OSIR Cytori Therapeutics, Inc. ThermoGenesis (KOOL) RTI Biologics (RTIX) Aastrom Biosciences -ASTM Amgen: FDA To Give Priority Review To D...
Published:Fri, 16 Jul 2010 15:40:40 -0700
Amgen: FDA To Give Priority Review To Denosumab For Cancer......
Published:Fri, 16 Jul 2010 15:40:40 -0700
Amgen: FDA To Give Priority Review To Denosumab For Cancer......
Amgen Taps Novartis Alum For CFO Post...
Published:Thu, 15 Jul 2010 12:54:04 -0700
Amgen appoints Jonathan Peacock as its new chief financial officer effective September 1.......
Published:Thu, 15 Jul 2010 12:54:04 -0700
Amgen appoints Jonathan Peacock as its new chief financial officer effective September 1.......
Amgen granted FDA priority review desig...
Published:Fri, 16 Jul 2010 22:22:34 -0700
Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatmen......
Published:Fri, 16 Jul 2010 22:22:34 -0700
Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatmen......
Amgen drug gets priority review for bon...
Published:Fri, 16 Jul 2010 15:43:42 -0700
SAN FRANCSICO (MarketWatch) -- Amgen Inc. said late Friday that the Food and Drug Administration will give the company a priority review for its drug denosumab as a bone cancer tr......
Published:Fri, 16 Jul 2010 15:43:42 -0700
SAN FRANCSICO (MarketWatch) -- Amgen Inc. said late Friday that the Food and Drug Administration will give the company a priority review for its drug denosumab as a bone cancer tr......
Amgen names new financial officer...
Published:Thu, 15 Jul 2010 22:14:00 -0700
Amgen names new CFO.......
Published:Thu, 15 Jul 2010 22:14:00 -0700
Amgen names new CFO.......
